- Title
- Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
- Creators
- Mikkael A SekeresJustin WattsAtanas RadinoffMontserrat Arnan SangermanMarco CerranoPatricia Font LopezJoshua F ZeidnerMaria Diez CampeloCarlos GrauxJane LiesveldDominik SelleslagNikolay TzvetkovRobert J FramDan ZhaoJill BellSharon FriedlanderDouglas V FallerLionel Adès
- Publication Details
- Leukemia, Vol.35(12), pp.3637-3637
- Academic Unit
- Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
- Language
- English
- Resource Type
- Journal article
- Record Identifier
- 991031660550702976
Journal article
Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
Leukemia, Vol.35(12), pp.3637-3637
2021-11-17
Metrics
6 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Citation topics
- 1 Clinical & Life Sciences
- 1.103 Blood Disorders
- 1.103.155 Acute Myeloid Leukemia
- Web Of Science research areas
- Hematology
- Oncology
- ESI research areas
- Clinical Medicine
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites